

Adil I Daud

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5562689/publications.pdf>

Version: 2024-02-01

247
papers

37,561
citations

10986

71
h-index

3034

188
g-index

255
all docs

255
docs citations

255
times ranked

37023
citing authors

#	ARTICLE	IF	CITATIONS
1	The Liver's "Immunity Nexus and Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2022, 28, 5-12.	7.0	47
2	Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy. <i>Cellular and Molecular Immunology</i> , 2022, 19, 33-45.	10.5	47
3	Discovering dominant tumor immune archetypes in a pan-cancer census. <i>Cell</i> , 2022, 185, 184-203.e19.	28.9	70
4	TCR-sequencing in cancer and autoimmunity: barcodes and beyond. <i>Trends in Immunology</i> , 2022, 43, 180-194.	6.8	20
5	Intratumoral Electroporation of Plasmid Encoded IL12 and Membrane-Anchored Anti-CD3 Increases Systemic Tumor Immunity. <i>Molecular Cancer Research</i> , 2022, 20, 983-995.	3.4	8
6	Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity. <i>Molecular Therapy - Oncolytics</i> , 2022, 25, 174-188.	4.4	5
7	Intratumoral therapies and in-situ vaccination for melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1890512.	3.3	8
8	The State of Melanoma: Emergent Challenges and Opportunities. <i>Clinical Cancer Research</i> , 2021, 27, 2678-2697.	7.0	53
9	Response to PD-1 Immunotherapy in Metastatic Spiradenocarcinoma. <i>JCO Precision Oncology</i> , 2021, 5, 340-343.	3.0	1
10	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2021, 144, 182-191.	2.8	57
11	Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	74
12	Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. , 2021, 9, e002478.		59
13	Pembrolizumab and Ipilimumab as Second-Line Therapy for Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2637-2639.	1.6	4
14	Layilin Anchors Regulatory T Cells in Skin. <i>Journal of Immunology</i> , 2021, 207, 1763-1775.	0.8	5
15	Should Sentinel Lymph Node Biopsy Status Guide Adjuvant Radiation Therapy in Patients With Merkel Cell Carcinoma?. <i>Advances in Radiation Oncology</i> , 2021, 6, 100764.	1.2	1
16	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. <i>European Journal of Cancer</i> , 2021, 157, 391-402.	2.8	13
17	Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. <i>Science Immunology</i> , 2020, 5, .	11.9	148
18	Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. <i>Nature Medicine</i> , 2020, 26, 1564-1568.	30.7	71

#	ARTICLE	IF	CITATIONS
19	Treatment of Metastatic Melanoma With Leptomeningeal Disease Using Intrathecal Immunotherapy. <i>JCO Oncology Practice</i> , 2020, 16, 757-759.	2.9	9
20	Association of <i>BRAF</i> V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma. <i>JAMA Oncology</i> , 2020, 6, 1256.	7.1	38
21	Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. <i>Nature Communications</i> , 2020, 11, 3584.	12.8	115
22	Layilin augments integrin activation to promote antitumor immunity. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	28
23	Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 2827-2837.	7.0	86
24	ASO Author Reflections: Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 4131-4132.	1.5	0
25	Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 4122-4130.	1.5	7
26	Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. <i>Annals of Oncology</i> , 2020, 31, 532-540.	1.2	82
27	Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutant Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 46-53.	7.0	32
28	Prognostic Biomarkers for Melanoma Immunotherapy. <i>Current Oncology Reports</i> , 2020, 22, 25.	4.0	13
29	Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses. <i>Cancer Immunology Research</i> , 2020, 8, 246-254.	3.4	61
30	Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 598-607.	7.0	63
31	Combinatorial Approach to Treatment of Melanoma. , 2019, , 687-697.		0
32	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 1239-1251.	10.7	812
33	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	10.7	155
34	An analysis of genetic heterogeneity in untreated cancers. <i>Nature Reviews Cancer</i> , 2019, 19, 639-650.	28.4	139
35	Clonal Deletion of Tumor-Specific T Cells by Interferon- γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. <i>Immunity</i> , 2019, 50, 477-492.e8.	14.3	93
36	Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. <i>Annals of Oncology</i> , 2019, 30, 582-588.	1.2	641

#	ARTICLE	IF	CITATIONS
37	Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 781-796.	6.7	11
38	Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity. <i>Cell</i> , 2019, 177, 556-571.e16.	28.9	405
39	Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 693-702.	1.6	274
40	A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 603-606.	3.3	18
41	Regulatory T cells use arginase 2 to enhance their metabolic fitness in tissues. <i>JCI Insight</i> , 2019, 4, .	5.0	60
42	PTCH1 Mutation in a Patient With Metastatic Undifferentiated Carcinoma With Clear Cell Change. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 778-783.	4.9	6
43	The gut microbiota and immune checkpoint inhibitors. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2178-2182.	3.3	28
44	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2018, 24, 4960-4967.	7.0	222
45	Revisiting RECIST: the case of treatment beyond progression. <i>Lancet Oncology</i> , The, 2018, 19, 157-159.	10.7	2
46	Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS mutant and wild-type melanoma. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 110-114.	3.3	55
47	Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. <i>European Journal of Cancer</i> , 2018, 91, 168-170.	2.8	33
48	Long-Term Outcomes in Patients With BRAF V600E Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2018, 36, 667-673.	1.6	196
49	Efficacy of pembrolizumab (Pembro) in patients (Pts) with advanced melanoma with stable brain metastases (BM) at baseline: A pooled retrospective analysis. <i>Annals of Oncology</i> , 2018, 29, viii444.	1.2	0
50	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator-Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 383-390.	1.6	431
51	Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 1668-1674.	1.6	360
52	Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. <i>Frontiers in Medicine</i> , 2018, 5, 351.	2.6	67
53	Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN- γ and IL-12. <i>Immunity</i> , 2018, 49, 1148-1161.e7.	14.3	639
54	Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. <i>British Journal of Cancer</i> , 2018, 119, 670-674.	6.4	114

#	ARTICLE	IF	CITATIONS
55	A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. <i>Nature Medicine</i> , 2018, 24, 1178-1191.	30.7	679
56	In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series. , 2018, 6, 43.		37
57	The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma. <i>Scientific Reports</i> , 2018, 8, 10902.	3.3	19
58	Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 5250-5260.	7.0	116
59	Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. <i>European Journal of Cancer</i> , 2018, 101, 236-243.	2.8	100
60	Current Immunotherapy of Melanoma. , 2018, , 567-576.		0
61	Negative but not futile: MAGE-A3 immunotherapeutic for melanoma. <i>Lancet Oncology</i> , The, 2018, 19, 852-853.	10.7	7
62	4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9503-9503.	1.6	71
63	Epacadostat plus nivolumab for advanced melanoma: Updated phase 2 results of the ECHO-204 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9511-9511.	1.6	39
64	5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9516-9516.	1.6	32
65	Immunotherapy for melanoma. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2018, 37, 127-131.	1.6	28
66	Combinatorial Approach to Treatment of Melanoma. , 2018, , 1-11.		0
67	Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. <i>British Journal of Cancer</i> , 2017, 116, 432-440.	6.4	59
68	Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. <i>Journal of Hematology and Oncology</i> , 2017, 10, 3.	17.0	47
69	Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. <i>Cancer Immunology Research</i> , 2017, 5, 417-424.	3.4	400
70	Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. <i>Annals of Oncology</i> , 2017, 28, 1380-1387.	1.2	134
71	Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. <i>British Journal of Cancer</i> , 2017, 116, 1141-1147.	6.4	112
72	Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12.) Tj ETQq0 0 0 rgBT /Qverlock 10 Tf 50 62	2.0	42

#	ARTICLE	IF	CITATIONS
73	Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. <i>Journal of Immunotherapy</i> , 2017, 40, 334-340.	2.4	16
74	Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2017, 86, 296-304.	2.8	64
75	Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy Summary of Advances and Future Directions for Studying These Drugs. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 3-9.	2.0	5
76	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). <i>Lancet, The</i> , 2017, 390, 1853-1862.	13.7	1,032
77	Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. <i>Oncologist</i> , 2017, 22, 823-833.	3.7	69
78	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. <i>European Journal of Cancer</i> , 2017, 86, 37-45.	2.8	183
79	Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. <i>JCI Insight</i> , 2017, 2, .	5.0	62
80	Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I/II results of ECHO-204.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3003-3003.	1.6	69
81	Relationship between liver metastases and PD-1 blockade in melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3072-3072.	1.6	3
82	Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9504-9504.	1.6	53
83	Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with <i>BRAF</i> V600 mutant unresectable or metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9505-9505.	1.6	7
84	Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9510-9510.	1.6	42
85	Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO1 to predict outcomes to anti-PD-1 in metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9517-9517.	1.6	2
86	Phase 1b/2 trial of ribociclib+binimetinib in metastatic <i>NRAS</i> -mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9519-9519.	1.6	32
87	Sexual activity and function in male cancer patients receiving targeted an immune therapies.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21594-e21594.	1.6	1
88	Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS3099-TPS3099.	1.6	23
89	Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12).. <i>Journal of Clinical Oncology</i> , 2017, 35, 78-78.	1.6	3
90	Patient attitudes toward oncofertility care in male cancer patients receiving targeted and immune therapies.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21593-e21593.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Abstract 683A: Mechanism of liver metastasis induced systemic suppression of checkpoint inhibitor response. , 2017, , .		0
92	Melanotic Schwannoma. <i>AJSP Review and Reports</i> , 2017, 22, 161-163.	0.1	0
93	Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 3447-3452.	8.2	439
94	Part II: Checkpoint inhibitors in cancer therapy. <i>Immunotherapy</i> , 2016, 8, 761-762.	2.0	1
95	Part I: Checkpoint inhibitors in cancer therapy. <i>Immunotherapy</i> , 2016, 8, 675-676.	2.0	2
96	Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade. , 2016, 4, 58.		35
97	A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. <i>Annals of Oncology</i> , 2016, 27, 947-952.	1.2	24
98	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1600.	7.4	857
99	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 2542-2552.	27.0	1,048
100	Pembrolizumab for melanoma- safety profile and future trends. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 727-729.	2.4	9
101	Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. <i>European Journal of Cancer</i> , 2016, 67, 46-54.	2.8	77
102	Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4102-4109.	1.6	528
103	Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. <i>Cancer</i> , 2016, 122, 3344-3353.	4.1	288
104	Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma. <i>Immunotherapy</i> , 2016, 8, 775-784.	2.0	24
105	Tumor response from phase II study of combination treatment with intratumoral HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIB, IIIC, or IV unresectable or metastatic melanoma. <i>Annals of Oncology</i> , 2016, 27, vi393.	1.2	2
106	Overall Survival and Durable Responses in Patients With BRAF V600E Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2016, 34, 871-878.	1.6	266
107	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. <i>Journal of Clinical Oncology</i> , 2016, 34, 1510-1517.	1.6	627
108	Abstract CT134: Intratumoral electroporation of plasmid IL-12 can prime response to anti-PD1/PD-L1 blockade in patients with Stage III/IV-M1a melanoma. <i>Cancer Research</i> , 2016, 76, CT134-CT134.	0.9	4

#	ARTICLE	IF	CITATIONS
109	Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9503-9503.	1.6	98
110	Efficacy and safety of programmed death receptor-1 (PD-1) blockade in metastatic uveal melanoma (UM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9507-9507.	1.6	5
111	KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9513-9513.	1.6	8
112	Derivation and validation of a prediction scale for response to PD-1 monotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9514-9514.	1.6	2
113	Novel T cell exhaustion marker to predict monotherapy PD-1 compared to combination CTLA-4 and PD-1 response in melanoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9520-9520.	1.6	3
114	Preliminary results from phase II study of combination treatment with HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIb, IIIc, or IV unresectable or metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9543-9543.	1.6	14
115	Correlation between metastatic site and response to anti-Programmed Death-1 (PD-1) agents in melanoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9549-9549.	1.6	12
116	Correlation between local 18F-fluorodeoxyglucose PET/CT and T cell exhaustion for predicting treatment response in patients with advanced melanoma treated with checkpoint inhibitor mono-therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11572-11572.	1.6	0
117	Tumor intrinsic resistance to anti-programmed death 1. <i>Translational Cancer Research</i> , 2016, 5, S1515-S1520.	1.0	0
118	A Review of Novel Intralesional Therapies for Melanoma, With an Emphasis on a Potential Combination Approach. <i>Oncology</i> , 2016, 30, 442-3.	0.5	2
119	Combined dabrafenib and trametinib therapy in metastatic melanoma and organ transplantation: Case report and review of the literature. <i>JAAD Case Reports</i> , 2015, 1, S23-S25.	0.8	12
120	Nivolumab plus ipilimumab in the treatment of advanced melanoma. <i>Journal of Hematology and Oncology</i> , 2015, 8, 123.	17.0	42
121	Long-term overall survival from a phase I trial using intratumoral plasmid interleukin-12 with electroporation in patients with melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, .	4.4	4
122	Phase I Study of Pembrolizumab (MK-3475; Anti-“PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 4286-4293.	7.0	627
123	Current and Emerging Perspectives on Immunotherapy for Melanoma. <i>Seminars in Oncology</i> , 2015, 42, S3-S11.	2.2	19
124	Future of combination therapy with dabrafenib and trametinib in metastatic melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2257-2263.	1.8	9
125	Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. <i>Annals of Oncology</i> , 2015, 26, 415-421.	1.2	78
126	Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 1060-1066.	1.6	161

#	ARTICLE	IF	CITATIONS
127	Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. <i>JAMA Dermatology</i> , 2015, 151, 1206.	4.1	385
128	The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. <i>British Journal of Cancer</i> , 2015, 112, 1326-1331.	6.4	30
129	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 908-918.	10.7	1,419
130	Pembrolizumab versus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2015, 372, 2521-2532.	27.0	4,838
131	Intratumoral electroporation of plasmid interleukin-12: efficacy and biomarker analyses from a phase 2 study in melanoma (OMS-I100). <i>Journal of Translational Medicine</i> , 2015, 13, O11.	4.4	5
132	A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, O5.	4.4	23
133	The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. <i>Drugs</i> , 2015, 75, 563-575.	10.9	18
134	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in <i>BRAF</i> V600E Mutant Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4023-4031.	1.6	430
135	Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. <i>Annals of Oncology</i> , 2015, 26, 2173-2179.	1.2	74
136	Abstract 2857: Metastatic site and response to pembrolizumab (anti-PD1 antibody) in melanoma. <i>Cancer Research</i> , 2015, 75, 2857-2857.	0.9	8
137	Abstract CT101: Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naïve advanced melanoma. , 2015, , .		2
138	Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3000-3000.	1.6	14
139	Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3001-3001.	1.6	140
140	Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2015, 33, 3012-3012.	1.6	18
141	Population pharmacokinetic (popPK) model of pembrolizumab (pembro; MK-3475) in patients (pts) treated in KEYNOTE-001 and KEYNOTE-002.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3058-3058.	1.6	4
142	Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3068-3068.	1.6	4
143	Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9005-9005.	1.6	52
144	Clinical characteristics predictive of response to pembrolizumab in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9031-9031.	1.6	10

#	ARTICLE	IF	CITATIONS
145	Patient-reported outcomes (PROs) in KEYNOTE-002, a randomized study of pembrolizumab vs chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) metastatic melanoma (MEL).. Journal of Clinical Oncology, 2015, 33, 9040-9040.	1.6	2
146	Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001.. Journal of Clinical Oncology, 2015, 33, 9050-9050.	1.6	9
147	Deep profiling of tumor immune microenvironment (TME) with fluorescence activated cell sorting (FACS) in advanced melanoma.. Journal of Clinical Oncology, 2015, 33, 9012-9012.	1.6	1
148	Abstract B65: Dissecting the tumor myeloid compartment reveals rare activating antigen presenting cells, critical for T cell immunity. Cancer Immunology Research, 2015, 3, B65-B65.	3.4	3
149	PD-1 and PD-L1 antibodies for melanoma. Human Vaccines and Immunotherapeutics, 2014, 10, 3111-3116.	3.3	54
150	Melanoma immunotherapy. Cancer Biology and Therapy, 2014, 15, 665-674.	3.4	73
151	The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. Journal of Clinical Pharmacology, 2014, 54, 368-374.	2.0	41
152	Involution of Eruptive Melanocytic Nevi on Combination BRAF and MEK Inhibitor Therapy. JAMA Dermatology, 2014, 150, 1209.	4.1	28
153	A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma. Cancer Chemotherapy and Pharmacology, 2014, 73, 103-111.	2.3	45
154	Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF ^{V600} -Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. Journal of Clinical Oncology, 2014, 32, 3697-3704.	1.6	173
155	Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. Journal of the American Academy of Dermatology, 2014, 71, 1102-1109.e1.	1.2	67
156	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet, The, 2014, 384, 1109-1117.	13.7	1,588
157	Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity. Cancer Cell, 2014, 26, 638-652.	16.8	911
158	Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study. Lancet Oncology, The, 2014, 15, 954-965.	10.7	225
159	Combinatorial Approach to Treatment of Melanoma. Hematology/Oncology Clinics of North America, 2014, 28, 601-612.	2.2	3
160	Management of a Patient With Advanced BRAF-Mutant Melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 315-319.	4.9	1
161	Melanoma, Version 4.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 621-629.	4.9	61
162	Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)., 2014, 2, .		11

#	ARTICLE	IF	CITATIONS
163	Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome. Cancer Research, 2014, 74, CT104-CT104.	0.9	23
164	Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naïve (IPI-N) melanoma (MEL).. Journal of Clinical Oncology, 2014, 32, 3000-3000.	1.6	11
165	Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.. Journal of Clinical Oncology, 2014, 32, 3005-3005.	1.6	58
166	Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.. Journal of Clinical Oncology, 2014, 32, 3006-3006.	1.6	23
167	Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.. Journal of Clinical Oncology, 2014, 32, 3015-3015.	1.6	22
168	Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis.. Journal of Clinical Oncology, 2014, 32, 3517-3517.	1.6	17
169	Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma.. Journal of Clinical Oncology, 2014, 32, 9006-9006.	1.6	3
170	Updated overall survival (OS) for BR113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with <i>BRAF</i> V600 mutation-positive (+) metastatic melanoma (MM).. Journal of Clinical Oncology, 2014, 32, 9010-9010.	1.6	13
171	Systemic antitumor effect and clinical response in a phase 2 trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma.. Journal of Clinical Oncology, 2014, 32, 9025-9025.	1.6	18
172	A phase I trial of BKM120 combined with vemurafenib in BRAFV600^{E/k} mutant advanced melanoma.. Journal of Clinical Oncology, 2014, 32, 9101-9101.	1.6	9
173	Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).. Journal of Clinical Oncology, 2014, 32, LBA9000-LBA9000.	1.6	48
174	Safety and Tumor Responses with LAMBROLIZUMAB (Anti-â€œPD-1) in Melanoma. New England Journal of Medicine, 2013, 369, 134-144.	27.0	3,128
175	Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4015-4020.	7.1	203
176	Removing the Unknown From the Carcinoma of Unknown Primary. Journal of Clinical Oncology, 2013, 31, 174-175.	1.6	12
177	Reply to M.-E. Percival et al and L.B. Saltz. Journal of Clinical Oncology, 2013, 31, 2515-2516.	1.6	0
178	Melanoma, Version 2.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 395-407.	4.9	134
179	BKM120 combined with vemurafenib in vemurafenib-refractory BRAF mutant metastatic melanoma: Two cases.. Journal of Clinical Oncology, 2013, 31, e20010-e20010.	1.6	2
180	Phase I study of pazopanib (PAZ) in combination with PCI-24781 (PCI) in patients (pts) with metastatic solid tumors with new tumor proliferation imaging correlates in renal cell carcinoma (RCC) and sarcoma.. Journal of Clinical Oncology, 2013, 31, TPS2623-TPS2623.	1.6	0

#	ARTICLE	IF	CITATIONS
181	Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 1092-1100.	7.0	78
182	Plasmid IL-12 electroporation in melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1734-1738.	3.3	35
183	Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. <i>British Journal of Cancer</i> , 2012, 106, 85-91.	6.4	38
184	BEAM Trial: Lighting the Way Ahead?. <i>Journal of Clinical Oncology</i> , 2012, 30, 6-7.	1.6	5
185	Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 366-400.	4.9	63
186	Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. <i>New England Journal of Medicine</i> , 2012, 367, 1694-1703.	27.0	2,445
187	Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1087-1099.	3.1	22
188	Cutting Edge in Medical Management of Cutaneous Oncology. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2012, 31, 140-149.	1.6	7
189	A clinical and translational phase II trial of sequential axitinib and carboplatin/paclitaxel in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8580-8580.	1.6	0
190	Tumor Fistulization Associated With Targeted Therapy. <i>Journal of Computer Assisted Tomography</i> , 2011, 35, 86-90.	0.9	18
191	An isolated Merkel cell carcinoma metastasis at a distant cutaneous site presenting as a second "primary" tumor. <i>Journal of Cutaneous Pathology</i> , 2011, 38, no-no.	1.3	15
192	Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α -2b in patients with resected high-risk melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 657-666.	2.3	22
193	Cutaneous melanoma: A model to study cancer metastasis. <i>Journal of Surgical Oncology</i> , 2011, 103, 538-549.	1.7	38
194	Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 1565-1574.	4.1	32
195	NRAS-Mutant Melanoma: Response to Chemotherapy. <i>Archives of Dermatology</i> , 2011, 147, 626.	1.4	1
196	Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264-272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies. <i>Clinical Cancer Research</i> , 2011, 17, 7765-7775.	7.0	49
197	Protein Kinase Inhibitors. , 2011, , 319-330.		0
198	Implementation of a High-Dose Interleukin-2 Immunostimulation Biotherapy Program. <i>ICU Director</i> , 2010, 1, 77-81.	0.2	2

#	ARTICLE	IF	CITATIONS
199	Changes in Dendritic Cell Phenotype After a New High-dose Weekly Schedule of Interleukin-2 Therapy for Kidney Cancer and Melanoma. <i>Journal of Immunotherapy</i> , 2010, 33, 817-827.	2.4	40
200	Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma. <i>British Journal of Cancer</i> , 2010, 103, 1548-1553.	6.4	16
201	Beyond BRAF in Melanoma. <i>Current Topics in Microbiology and Immunology</i> , 2010, 355, 99-117.	1.1	14
202	Treatment of cutaneous melanoma: current approaches and future prospects. <i>Cancer Management and Research</i> , 2010, 2, 197.	1.9	38
203	New horizons in melanoma treatment: targeting molecular pathways. <i>Ochsner Journal</i> , 2010, 10, 93-8.	1.1	1
204	Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 2823-2830.	1.6	517
205	Potential of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial. <i>Clinical Cancer Research</i> , 2009, 15, 2479-2487.	7.0	82
206	A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 903-910.	2.3	48
207	Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. <i>British Journal of Cancer</i> , 2009, 101, 1044-1050.	6.4	150
208	Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC. <i>Clinical Cancer Research</i> , 2009, 15, 2488-2496.	7.0	137
209	Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. <i>Melanoma Research</i> , 2009, 19, 167-175.	1.2	52
210	The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. <i>BMC Medical Genomics</i> , 2008, 1, 13.	1.5	425
211	State of the science 60th anniversary review. <i>Cancer</i> , 2008, 113, 1728-1743.	4.1	14
212	Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5896-5903.	1.6	613
213	Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin. <i>Journal of Clinical Oncology</i> , 2008, 26, 5198-5203.	1.6	229
214	Phenotypic and Functional Analysis of Dendritic Cells and Clinical Outcome in Patients With High-Risk Melanoma Treated With Adjuvant Granulocyte Macrophage Colony-Stimulating Factor. <i>Journal of Clinical Oncology</i> , 2008, 26, 3235-3241.	1.6	178
215	Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2008, 14, 8302-8307.	7.0	193
216	Melanoma: Promising New Discoveries and Treatment Modalities for Difficult Clinical Scenarios. <i>Cancer Control</i> , 2008, 15, 192-194.	1.8	1

#	ARTICLE	IF	CITATIONS
217	Activated Stat-3 in Melanoma. <i>Cancer Control</i> , 2008, 15, 196-201.	1.8	62
218	Melanoma Genomicsâ€™Techniques and Implications for Therapy. <i>Translational Medicine Series</i> , 2008, , 37-54.	0.0	0
219	Phase I Trial of Poly-<scp> </scp>-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2007, 13, 5855-5861.	7.0	98
220	Phase I Trial of Histone Deacetylase Inhibition by Valproic Acid Followed by the Topoisomerase II Inhibitor Epirubicin in Advanced Solid Tumors: A Clinical and Translational Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 1979-1985.	1.6	205
221	Spectrum of Activity and Mechanism of Action of VEGF/PDGF Inhibitors. <i>Cancer Control</i> , 2007, 14, 285-294.	1.8	145
222	The Src signaling pathway: a potential target in melanoma and other malignancies. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 91-100.	3.4	59
223	Down-Regulation of Pro-Apoptotic Genes is an Early Event in the Progression of Malignant Melanoma. <i>Annals of Surgical Oncology</i> , 2007, 14, 1416-1423.	1.5	18
224	Overall and Progression-Free Survival in Metastatic Melanoma: Analysis of a Single-Institution Database. <i>Cancer Control</i> , 2006, 13, 211-217.	1.8	20
225	Immunotherapy as part of a multidisciplinary approach to melanoma treatment. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 1.	3.0	23
226	Vascular endothelial growth factor (VEGF) inhibitors in cancer therapy: an update. <i>Women's Oncology Review</i> , 2006, 6, 127-136.	0.0	0
227	Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study. <i>Clinical Cancer Research</i> , 2006, 12, 4645-4651.	7.0	32
228	Evaluation of Toxicity following Electrically Mediated Interleukin-12 Gene Delivery in a B16 Mouse Melanoma Model. <i>Clinical Cancer Research</i> , 2006, 12, 3177-3183.	7.0	79
229	Current immunotherapy of melanoma. <i>Clinical and Applied Immunology Reviews</i> , 2005, 5, 111-132.	0.4	3
230	Cutaneous Melanoma: Prognostic Factors. <i>Cancer Control</i> , 2005, 12, 223-229.	1.8	98
231	Melanoma: Changes below the Surface. <i>Cancer Control</i> , 2005, 12, 217-218.	1.8	0
232	In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1993-2000.	4.1	71
233	Phase II Trial of Karenitecin in Patients with Malignant Melanoma: Clinical and Translational Study. <i>Clinical Cancer Research</i> , 2005, 11, 3009-3016.	7.0	56
234	Synergistic Interaction between Histone Deacetylase and Topoisomerase II Inhibitors Is Mediated through Topoisomerase II β . <i>Clinical Cancer Research</i> , 2005, 11, 8467-8475.	7.0	57

#	ARTICLE	IF	CITATIONS
235	Valproic Acid Alters Chromatin Structure by Regulation of Chromatin Modulation Proteins. <i>Cancer Research</i> , 2005, 65, 3815-3822.	0.9	191
236	Uncommon Manifestations of Common Malignancies. <i>Journal of Clinical Oncology</i> , 2004, 22, 3194-3195.	1.6	17
237	Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. <i>Journal of Cellular Biochemistry</i> , 2004, 92, 223-237.	2.6	176
238	Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. <i>Oncogene</i> , 2002, 21, 7001-7010.	5.9	391
239	A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. <i>Clinical Cancer Research</i> , 2002, 8, 2505-11.	7.0	339
240	New drugs in gynecologic cancer. <i>Current Treatment Options in Oncology</i> , 2001, 2, 119-128.	3.0	3
241	PURIFICATION AND CHARACTERIZATION OF A NOVEL 35-kDa PROTEIN FROM TRANSFORMED CARDIOMYOCYTES. <i>Cell Biology International</i> , 1999, 23, 299-306.	3.0	1
242	Mouse RAD50 Has Limited Epitopic Homology to p53 and Is Expressed in the Adult Myocardium. <i>Journal of Biological Chemistry</i> , 1996, 271, 29255-29264.	3.4	21
243	Potential Approaches for Myocardial Regeneration. <i>Annals of the New York Academy of Sciences</i> , 1995, 752, 446-454.	3.8	37
244	Characterization of Angiotensin I-Converting Enzyme (ACE)-Containing Follicles in the Rat Ovary during the Estrous Cycle and Effects of ACE Inhibitor on Ovulation*. <i>Endocrinology</i> , 1990, 126, 2927-2935.	2.8	43
245	Evidence for Selective Expression of Angiotensin II Receptors on Atretic Follicles in the Rat Ovary: An Autoradiographic Study*. <i>Endocrinology</i> , 1988, 122, 2727-2734.	2.8	87
246	Angiotensin II: An Intraovarian Regulatory Peptide. <i>American Journal of the Medical Sciences</i> , 1988, 295, 406-408.	1.1	47
247	Treatment of cutaneous melanoma: current approaches and future prospects. <i>Cancer Management and Research</i> , 0, , 197.	1.9	2